Delhi, India (PressExposure) April 25, 2007 -- The results of the stem cell therapy given to teenagers and young adults suffering from Type-1 diabetes were described to be âvery encouragingâ by the two researchers - Richard Burt of Northwestern University Feinberg School of Medicine, Chicago, and University of Sao Pauloâs Julio Voltarelli. The patients, on whom the test was done, could discontinue taking insulin following the successful knock out of their malfunctioning immune systems. The treatment also reconstructed them from their own stem cells.
Just after giving an injection of stem cells, a large number of patients did not feel the need to take another insulin injection, as the effect of the first injection lasted from one to 35 months.
Often, this type of diabetes (Type-1) is diagnosed in young adults or children. Itâs a gene linked disorder which affects approximately1.4 million Americans, as per the US Centers for Disease Control & Prevention. Even if controlled by taking insulin injections daily, Type-1 diabetes may result in complications such as heart disease, high blood pressure, limbsâ amputation, and circulation problems.
A treatment of Type-1 diabetes, which doesnât require multiple injections of insulin to be pricked everyday, is sure to offer a hope of a nearly needle free life for people suffering from this fatal and incapacitating disease.
The multi billion-dollar market of insulin can also be severely impacted by the successful stem cell treatment â a market wherein a barrage of various treatment revolutions either have or may continue to remain lackluster. For example, Exubera â the worldâs 1st and perhaps only inhaled insulin product developed by Pfizer â was once seen as a potential breakthrough drug. Sales of Exubera however have been particularly disappointing for pharmaceutical giant.
RNCOS report âNew Developments in Insulin Delivery System (2006)â notifies, âCurrent ambiance in insulin market comprises of strong marketing plus clinical support in favor of the newly launched products. Drug delivery productsâ sales will likely increase by 100% in the coming five years, since technologies being researched & developed currently will attain fruition and get commercialized by that time. Presently, special drug delivery technologyâs market value is US$ 50 Billion per year, i.e. 12.5% of global pharmaceutical sales.â
This research report âNew Developments in Insulin Delivery System (2006)â helps clients in analyzing the opportunities critical to the growth of Insulin Delivery Systems in the World. The report addresses some interesting issues for todayâs Global business environment, such as evaluation of current market trends, discussion about the leading edge technologies, scope of the major insulin delivery systems all over the world, analysis of various challenges and opportunities before the industry, etc.
About RNCOS E-Services Pvt Ltd.:
RNCOS, incorporated in the year 2002, is an industry research firm. It has a team of industry experts who analyze data collected from credible sources. They provide industry insights and analysis that helps corporations to take timely and accurate business decision in today's globally competitive environment. For more information visit: